HIF1A and pachyonychia congenita: Furthermore a precise understanding of the mechanisms behind the increased translation of HIF1α protein in PC cells may not only lead to identification of novel therapeutic targets to inhibit HIF1α expression, but may also guide the choice of which HIF1α inhibitor from the many available may work best in CRPC patients [60], [61].